Know Cancer

or
forgot password

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment,Post-Treatment and at Six Months Follow Up


N/A
21 Years
N/A
Open (Enrolling)
Both
Breast Cancer, Lymphoma

Thank you

Trial Information

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment,Post-Treatment and at Six Months Follow Up


Inclusion Criteria:



Subjects Receiving Chemotherapy:

- Have a diagnosis of invasive breast cancer (stage I-IIIC) or intermediate or
high-grade* lymphoma (*defined by the treating physician)

- Be scheduled to begin a course of chemotherapy

- Oral chemotherapy is acceptable

- Previous or concurrent treatment with hormones or biological response modifiers is
acceptable. (Subjects receiving biological response modifiers only are not eligible).

- Be chemotherapy naïve

- Life expectancy greater than 10 months

- Be able to speak and read English

- Give written informed consent

Inclusion Criteria, Controls:

- Must be the same gender as the subject receiving chemotherapy

- Must be within 5 years of the age of the subject receiving chemotherapy

- Life expectancy greater than 10 months

- Be able to speak and read English

- Give written informed consent

- Must be willing to participate in the study for the entire period

Exclusion Criteria:

Subjects Receiving Chemotherapy:

- Must not be currently hospitalized or have been hospitalized within the last year for
a psychiatric illness

- Must not be diagnosed with a neurodegenerative disease

- Must not have primary central nervous system (CNS) disease

- Must not have received chemotherapy in the past

- Must not be scheduled to receive concurrent radiation treatment

- Must not have metastatic disease (subjects with breast cancer)

- Must not be pregnant

- Must not be colorblind

Exclusion Criteria, Controls:

- Must not be currently hospitalized or have been hospitalized within the last year for
a psychiatric illness

- Must not be diagnosed with a neurodegenerative disease

- Must not have primary CNS disease

- Must not have been diagnosed with cancer or previously have received chemotherapy

- Must not be pregnant or plan on becoming pregnant during the study period

- Must not be colorblind

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Short-term memory

Outcome Description:

Short-term visual memory will be assessed by the computerized Delayed Matching to Sample (DMS) task.

Outcome Time Frame:

Before beginning chemotherapy, at completion of chemotherapy and 6 months later

Safety Issue:

No

Principal Investigator

Michelle C. Janelsins, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Rochester

Authority:

United States: Institutional Review Board

Study ID:

URCC 10055

NCT ID:

NCT01382082

Start Date:

July 2011

Completion Date:

April 2015

Related Keywords:

  • Breast Cancer
  • Lymphoma
  • cognitive function
  • memory
  • attention
  • breast cancer
  • lymphoma
  • Breast Neoplasms
  • Lymphoma

Name

Location

University of Rochester Cancer CenterRochester, New York  14642